PMS HYDROMORPHONE SUPPOSITOIRE 3MG SUPPOSITORY

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

HYDROMORPHONE HYDROCHLORIDE

Disponible depuis:

PHARMASCIENCE INC

Code ATC:

N02AA03

DCI (Dénomination commune internationale):

HYDROMORPHONE

Dosage:

3MG

forme pharmaceutique:

SUPPOSITORY

Composition:

HYDROMORPHONE HYDROCHLORIDE 3MG

Mode d'administration:

RECTAL

Unités en paquet:

10

Type d'ordonnance:

Narcotic (CDSA I)

Domaine thérapeutique:

OPIATE AGONISTS

Descriptif du produit:

Active ingredient group (AIG) number: 0108698002; AHFS:

Statut de autorisation:

MARKETED

Date de l'autorisation:

1991-12-31

Résumé des caractéristiques du produit

PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
N
PMS-HYDROMORPHONE
HYDROmorphone Hydrochloride
Tablets, 1 mg, 2 mg, 4 mg and 8 mg, Oral
Syrup, 1 mg/mL, Oral
Suppositories, 3 mg, Rectal
USP Standard
Opioid Analgesic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
Submission Control No.: 243864
DATE OF REVISION:
October 14, 2020
_pms-HYDROmorphone Prescribing Information _
_Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 3
1
INDICATIONS
......................................................................................................................
3
1.1
Pediatrics
.................................................................................................................
3
1.2
Geriatrics
.................................................................................................................
3
2
CONTRAINDICATIONS
.......................................................................................................
3
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.3
Administration
..........................................................................................................
7
4.4
Missed Dose
............................................................................................................
7
5
OVERDOSAGE
...................................................................................................................
8
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
.............................. 9
7
WARNINGS AND PRECAUTIONS